StockMacro
Menu

Celldex Therapeutics

$27.42 -11% in 6 monthsMarket cap $2.2B

CLDX on XNAS, Health Care, Celldex Therapeutics, Inc, job postings

Measures activity, not value. Not investment advice.

Net loss of $309.1M and free cash outflow of $259.7M, while shares are up 9.4% in a year.

  • BadShort interest at 13% of shares, up 3.5% on the earlier report

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.

Industry
In vitro & in vivo diagnostic substances (Health Care)
Employees
198
Website
celldex.com
Listed
Nasdaq, US
Last results
5 Nov 2026
Next results
expected around 24 Feb 2027 (an estimate: a year ago it reported on 25 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: net loss $75.6M.
Quarter to 31 Dec 2021: revenue $334K, net income -$20.1MQuarter to 31 Dec 2021: revenue $334K, net income -$20.1MQuarter to 31 Mar 2022: revenue $174K, net income -$23.1MQuarter to 31 Mar 2022: revenue $174K, net income -$23.1MQuarter to 30 Jun 2022: revenue $163K, net income -$36.0MQuarter to 30 Jun 2022: revenue $163K, net income -$36.0MQuarter to 30 Sep 2022: revenue $407K, net income -$26.8MQuarter to 30 Sep 2022: revenue $407K, net income -$26.8MQuarter to 31 Dec 2022: revenue –, net income -$26.5MQuarter to 31 Mar 2023: revenue $967K, net income -$29.4MQuarter to 31 Mar 2023: revenue $967K, net income -$29.4MQuarter to 30 Jun 2023: revenue $268K, net income -$30.5MQuarter to 30 Jun 2023: revenue $268K, net income -$30.5MQuarter to 30 Sep 2023: revenue $1.5M, net income -$38.3MQuarter to 30 Sep 2023: revenue $1.5M, net income -$38.3MQuarter to 31 Dec 2023: revenue $4.1M, net income -$43.3MQuarter to 31 Dec 2023: revenue $4.1M, net income -$43.3MQuarter to 31 Mar 2024: revenue $156K, net income -$32.8MQuarter to 31 Mar 2024: revenue $156K, net income -$32.8MQuarter to 30 Jun 2024: revenue $2.5M, net income -$35.8MQuarter to 30 Jun 2024: revenue $2.5M, net income -$35.8MQuarter to 30 Sep 2024: revenue $3.2M, net income -$42.1MQuarter to 30 Sep 2024: revenue $3.2M, net income -$42.1MQuarter to 31 Dec 2024: revenue $1.2M, net income -$47.1MQuarter to 31 Dec 2024: revenue $1.2M, net income -$47.1MQuarter to 31 Mar 2025: revenue $695K, net income -$53.8MQuarter to 31 Mar 2025: revenue $695K, net income -$53.8MQuarter to 30 Jun 2025: revenue $730K, net income -$56.6MQuarter to 30 Jun 2025: revenue $730K, net income -$56.6MQuarter to 30 Sep 2025: revenue –, net income -$67.0MQuarter to 31 Dec 2025: revenue $121K, net income -$81.3MQuarter to 31 Dec 2025: revenue $121K, net income -$81.3MQuarter to 31 Mar 2026: revenue $15K, net income -$78.7MQuarter to 31 Mar 2026: revenue $15K, net income -$78.7MQuarter to 30 Jun 2026: revenue $22K, net income -$73.5MQuarter to 30 Jun 2026: revenue $22K, net income -$73.5MQuarter to 30 Sep 2026: revenue –, net income -$75.6M
31 Dec 2021RevenueNet incomeNet losstallest bar $81.3M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026–-$75.6M
30 Jun 2026$22K-$73.5M
31 Mar 2026$15K-$78.7M
31 Dec 2025$121K-$81.3M
30 Sep 2025–-$67.0M
30 Jun 2025$730K-$56.6M
31 Mar 2025$695K-$53.8M
31 Dec 2024$1.2M-$47.1M
30 Sep 2024$3.2M-$42.1M
30 Jun 2024$2.5M-$35.8M
31 Mar 2024$156K-$32.8M
31 Dec 2023$4.1M-$43.3M
30 Sep 2023$1.5M-$38.3M
30 Jun 2023$268K-$30.5M
31 Mar 2023$967K-$29.4M
31 Dec 2022–-$26.5M
30 Sep 2022$407K-$26.8M
30 Jun 2022$163K-$36.0M
31 Mar 2022$174K-$23.1M
31 Dec 2021$334K-$20.1M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – -1.5%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$309.1M -$224.5M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$4.31 -$3.38
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 51.3%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -9.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -15.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -49.5% -40.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. -$259.7M -$181.7M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $650.3M $583.2M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 $0
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$650.3M (net cash) -$583.2M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.22
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $8.27
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 24.7
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 3.6
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 3.6
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 3.3 2.3

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Celldex TherapeuticsCLDX (this company) $2.2Bloss–––
NeogenNEOG $2.3Bloss2.6-0.3%-6.3%
Intellia TherapeuticsNTLA $1.4Bloss26.5-8.1%-806%
LantheusLNTH $6.7B24.74.3+2.4%17.3%
Achieve Life SciencesQUIT $611.8Mloss–––
QuidelOrthoQDEL $570.9Mloss0.22-4.5%-14.2%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

–

No data for this company

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

-0.8%

247 13F filers vs 249

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

over 100%

88.8M shares held by 13F filers (30 Sep 2026) of 78.5M outstanding (28 Oct 2026); above 100%: the share count is probably stale

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

13%

9.9M shares sold short (30 Oct 2026) of 78.5M outstanding (28 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

10.3

9.9M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+3.5%

9.6M shares sold short in the report before, 9.9M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

79%

79% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 56%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

37

Tracked since 21 Nov 2026

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

Tracking started 21 Nov 2026; the change shows after 30 days.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$270K

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

19

19 articles in the last 7 days; its usual week has 1 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

19×

19 articles in the last 7 days; its usual week has 1.

Price $27.42 on 20 Nov 2026, +9.4% over 12 months (12-month range $22.58 to $44.87)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $121K in the last 12 months (the 12 months before: -$1.2M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 2 published in the last 12 months, +100% on the 12 months before.
Revenue per quarter. Revenue $22K in the latest quarter, -97% on a year earlier.
Capital spending per quarter. Capital spending $1.7M in the latest quarter, +279% on a year earlier.
Institutional holders (13F filers). 247 13F filers reported holding it in the latest 13F quarter, +44% on a year earlier.
Federal obligations. Federal obligations: $0 published in the last 12 months.
Lobbying spend. Lobbying spend: $270K published in the last 12 months, +93% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
15 Jul 20268-K and other filingsDirector or officer change
26 Jun 20268-K and other filingsDirector or officer change
26 Jun 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
6 Jun 20258-K and other filingsDirector or officer change
6 Jun 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
5 Mar 2025Lobbying filingnew lobbying registration (AKIN GUMP STRAUSS HAUER & FELD)
5 Mar 2025Sharp changeFirst lobbying registration: first lobbying registration: CELLDEX THERAPEUTICS, INC.: new lobbying registration (AKIN GUMP STRAUSS HAUER & FELD)
14 Jun 20248-K and other filingsDirector or officer change
14 Jun 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
21 May 2024Sharp changeMany funds opening a new position: many funds opening a new position, 40 vs usual 19 (2024-03-31); 2.0x the same period a year earlier
21 Feb 20238-K and other filingsDirector or officer change
21 Feb 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Dec 2021: -$876K published
Month from 1 Aug 2022: -$7.7M published
Month from 1 Dec 2022: -$623K published
Month from 1 Jun 2024: -$12.1M published
Month from 1 Nov 2024: $308K published
Month from 1 Aug 2025: -$19K published
Month from 1 Nov 2025: -$1.2M published
Month from 1 Dec 2025: -$121K published
H-1B/E-3 applications certified
Quarter from 1 Jan 2022: 2 published
Quarter from 1 Jul 2022: 1 published
Quarter from 1 Jul 2023: 1 published
Quarter from 1 Oct 2023: 1 published
Quarter from 1 Oct 2024: 1 published
Quarter from 1 Jan 2025: 1 published
Quarter from 1 Jan 2026: 1 published
Quarter from 1 Apr 2026: 1 published
Revenue per quarter
Quarter ended 31 Dec 2021: $334K, -91% on a year earlier; public on 1 Mar 2022
Quarter ended 31 Mar 2022: $174K, -75% on a year earlier; public on 6 May 2022
Quarter ended 30 Jun 2022: $163K, -95% on a year earlier; public on 9 Aug 2022
Quarter ended 30 Sep 2022: $407K, +166% on a year earlier; public on 10 Nov 2022
Quarter ended 31 Mar 2023: $967K, +456% on a year earlier; public on 5 May 2023
Quarter ended 30 Jun 2023: $268K, +64% on a year earlier; public on 9 Aug 2023
Quarter ended 30 Sep 2023: $1.5M, +273% on a year earlier; public on 3 Nov 2023
Quarter ended 31 Dec 2023: $4.1M; public on 27 Feb 2024
Quarter ended 31 Mar 2024: $156K, -84% on a year earlier; public on 7 May 2024
Quarter ended 30 Jun 2024: $2.5M, +832% on a year earlier; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $3.2M, +110% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $1.2M, -72% on a year earlier; public on 28 Feb 2025
Quarter ended 31 Mar 2025: $695K, +346% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $730K, -71% on a year earlier; public on 8 Aug 2025
Quarter ended 31 Dec 2025: $121K, -90% on a year earlier; public on 26 Feb 2026
Quarter ended 31 Mar 2026: $15K, -98% on a year earlier; public on 8 May 2026
Quarter ended 30 Jun 2026: $22K, -97% on a year earlier; public on 7 Aug 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $354K, +43% on a year earlier; public on 1 Mar 2022
Quarter ended 31 Mar 2022: $575K, +1.4% on a year earlier; public on 6 May 2022
Quarter ended 30 Jun 2022: $673K, +371% on a year earlier; public on 9 Aug 2022
Quarter ended 30 Sep 2022: $345K, +86% on a year earlier; public on 10 Nov 2022
Quarter ended 31 Dec 2022: $235K, -34% on a year earlier; public on 1 Mar 2023
Quarter ended 31 Mar 2023: $585K, +1.7% on a year earlier; public on 5 May 2023
Quarter ended 30 Jun 2023: $410K, -39% on a year earlier; public on 9 Aug 2023
Quarter ended 30 Sep 2023: $157K, -54% on a year earlier; public on 3 Nov 2023
Quarter ended 31 Dec 2023: $666K, +183% on a year earlier; public on 27 Feb 2024
Quarter ended 31 Mar 2024: $344K, -41% on a year earlier; public on 7 May 2024
Quarter ended 30 Jun 2024: $274K, -33% on a year earlier; public on 9 Aug 2024
Quarter ended 30 Sep 2024: $545K, +247% on a year earlier; public on 7 Nov 2024
Quarter ended 31 Dec 2024: $756K, +14% on a year earlier; public on 28 Feb 2025
Quarter ended 31 Mar 2025: $265K, -23% on a year earlier; public on 9 May 2025
Quarter ended 30 Jun 2025: $728K, +166% on a year earlier; public on 8 Aug 2025
Quarter ended 30 Sep 2025: $440K, -19% on a year earlier; public on 11 Nov 2025
Quarter ended 31 Dec 2025: $1.3M, +69% on a year earlier; public on 26 Feb 2026
Quarter ended 31 Mar 2026: $1.6M, +518% on a year earlier; public on 8 May 2026
Quarter ended 30 Jun 2026: $3.2M, +337% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $1.7M, +279% on a year earlier; public on 6 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 159; public on 14 Feb 2022
31 Mar 2022 report: 158; public on 16 May 2022
30 Jun 2022 report: 150; public on 15 Aug 2022
30 Sep 2022 report: 147; public on 14 Nov 2022
31 Dec 2022 report: 157; public on 14 Feb 2023
31 Mar 2023 report: 153; public on 15 May 2023
30 Jun 2023 report: 141; public on 14 Aug 2023
30 Sep 2023 report: 135; public on 14 Nov 2023
31 Dec 2023 report: 152; public on 14 Feb 2024
31 Mar 2024 report: 188; public on 15 May 2024
30 Jun 2024 report: 174; public on 14 Aug 2024
30 Sep 2024 report: 172; public on 14 Nov 2024
31 Dec 2024 report: 174; public on 14 Feb 2025
31 Mar 2025 report: 169; public on 15 May 2025
30 Jun 2025 report: 175; public on 14 Aug 2025
30 Sep 2025 report: 172; public on 14 Nov 2025
31 Dec 2025 report: 182; public on 17 Feb 2026
31 Mar 2026 report: 221; public on 15 May 2026
30 Jun 2026 report: 249; public on 14 Aug 2026
30 Sep 2026 report: 247; public on 16 Nov 2026
Federal obligations
Month from 1 Sep 2022: $0 published
Month from 1 May 2023: -$1.5M published
Lobbying spend
Quarter from 1 Apr 2025: $20K published
Quarter from 1 Jul 2025: $60K published
Quarter from 1 Oct 2025: $60K published
Quarter from 1 Jan 2026: $60K published
Quarter from 1 Apr 2026: $60K published
Quarter from 1 Jul 2026: $90K published
Quarter from 1 Oct 2026: $60K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is insider open-market selling (USD, Form 4) at $121K (8 Dec 2025), 91% below its normal reading of $1.4M; higher than 38% of its own history.
  • Insider net buying (open market): Insiders sold a net $121K in the last 12 months (the 12 months before: -$1.2M).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 2 published in the last 12 months, +100% on the 12 months before.
  • Revenue per quarter: Revenue $22K in the latest quarter, -97% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 43 insider trades

No trades in the last 90 days; the latest was filed 8 Dec 2025. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
8 Dec 2025Freddy A. JimenezSVP & GENERAL COUNSELSell4,166$29.10$121KForm 4
17 Nov 2025Richard M. WrightFormer OfficerSellafter exercising options49,298$24.00$1.2MForm 4
15 Aug 2025Freddy A. JimenezSVP & GENERAL COUNSELSell771$24.77$19KForm 4
12 Nov 2024Anthony S MarucciPRESIDENT & CEOBuy11,500$26.82$308KForm 4
18 Jun 2024Elizabeth CrowleySR. VP & CPDOSellafter exercising options30,000$34.87$1.0MForm 4
18 Jun 2024Samuel Bates MartinSVP AND CFOSellafter exercising options17,172$35.42$608KForm 4
11 Jun 2024Elizabeth CrowleySR. VP & CPDOSellafter exercising options15,000$35.06$526KForm 4
11 Jun 2024Diane C. YoungSVP, CHIEF MEDICAL OFFICERSell45,000$35.26$1.6MForm 4

247 institutions reported shares at the end of Q3 2026, 100% of the shares outstanding; 34 opened a position, 38 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Wellington Management Group LLP10.7M13.6%$345.9M+1.1M+12%
FMR LLC (Fidelity)8.6M11.0%$279.9M+4.9M+132%
BlackRock, Inc.6.9M8.85%$225.2M-54K-0.8%
Kynam Capital Management, LP5.1M6.45%$164.2M-257K-4.8%
T. Rowe Price Associates Inc4.4M5.58%-299K-6.4%
State Street Corp3.5M4.43%$112.7M-422K-11%
Vanguard Capital Management LLC3.5M4.43%$112.7M+11K+0.3%
Baker Bros. Advisors LP2.6M3.27%$83.1M+1.4M+117%
Deep Track Capital, LP2.1M2.71%$68.9M-814K-28%
Geode Capital Management, LLC2.0M2.61%$66.4M+27K+1.3%

Company events

All 35 company events

In 12 months: 2 director or officer changes, 1 major agreement. Results releases and routine reports are left out.

FiledWhat happenedSource
15 Jul 2026Director or officer change8-K
26 Jun 2026Director or officer changeSame filing: shareholder vote results8-K
2 Apr 2026Signed a major agreement8-K
6 Jun 2025Director or officer changeSame filing: shareholder vote results8-K
14 Jun 2024Director or officer changeSame filing: shareholder vote results8-K
1 Mar 2024Signed a major agreement8-K
8 Nov 2023Signed a major agreement8-K
21 Feb 2023Director or officer change8-K

37 open postings; careers site tracked since 21 Nov 2026. Most in Finance & accounting 5%, Manufacturing & production 5%, Marketing & communications 5%, Operations & administration 5%.

PostedJobLocation
21 Nov 2026or earlierExecutive Director, Medical AffairsUS-NJ-Hampton
21 Nov 2026or earlierSenior Director, Commercial Learning and Development and Onboarding (Remote)People & recruitingUS-NJ-Hampton
21 Nov 2026or earlierGlobal Clinical Project LeaderProgram & project managementUS-CT-New Haven; US-NJ-Hampton
21 Nov 2026or earlierVice President, Pharmacovigilance & Risk ManagementOperations & administrationUS-NJ-Hampton
21 Nov 2026or earlierDirector, Supply Chain Planner - CommercialSupply chain & procurementUS-NJ-Hampton
21 Nov 2026or earlierSenior Medical Science Liaison _ SoutheastUS-NJ-Hampton; US-GA-Atlanta
21 Nov 2026or earlierExecutive Medical Science Liaison _ Washington DCUS-NJ-Hampton; US-DC-Washington
21 Nov 2026or earlierSenior Medical Science Liaison _ North CentralUS-NJ-Hampton; US-IL-Chicago

Reported lobbying spend: $60K in Q3 2026, $90K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
19 Feb 2025NewAkin Gump Strauss Hauer & Feldfor Celldex Therapeutics, Inc.Issues related to biotechnology policy.Health issuesFiling

The 5 newest of 94 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

16 Feb 2021confirmed

Confirmed across sources Institutional holdings and Short interest and volume

Celldex Therapeutics (CLDX): had 4.8M shares sold short in the 31 Dec 2020 report, 16× the same report last year, while it saw 41 13F filers open a new position in the quarter ended 31 Dec 2020, 6.8× the same quarter last year. Two unrelated kinds of activity within 28 days.

  • Short interest and volume: Short interest spike, became public on 13 Jan 2021
  • Institutional holdings: Many funds opening a new position, became public on 16 Feb 2021
2019-12-31: 310K2020-01-15: 284K2020-01-31: 266K2020-02-14: 244K2020-02-28: 381K2020-03-13: 415K2020-03-31: 322K2020-04-15: 315K2020-04-30: 307K2020-05-15: 264K2020-05-29: 301K2020-06-15: 2.3M2020-06-30: 1.5M2020-07-15: 951K2020-07-31: 787K2020-08-14: 1.2M2020-08-31: 2.4M2020-09-15: 3.0M2020-09-30: 3.3M2020-10-15: 3.2M2020-10-30: 3.0M2020-11-13: 2.8M2020-11-30: 2.4M2020-12-15: 2.2M2020-12-31: 4.8M
The 31 Dec 2020 report against the 24 reports before it. this reportearliernormal: 869K
See the evidence (2 changes)

Short interest and volume: Short interest spike became public on 13 Jan 2021

Celldex Therapeutics had 4.8M shares sold short in the 31 Dec 2020 report, 16× the same report last year.

This period
4.8M (the 31 Dec 2020 report)
Normal report (median of 24 earlier)
869K
Typical spread (median absolute deviation)
604K
How far from its usual level
+4.4
Same report last year
310K
History used
1,098 days
2019-12-31: 310K2020-01-15: 284K2020-01-31: 266K2020-02-14: 244K2020-02-28: 381K2020-03-13: 415K2020-03-31: 322K2020-04-15: 315K2020-04-30: 307K2020-05-15: 264K2020-05-29: 301K2020-06-15: 2.3M2020-06-30: 1.5M2020-07-15: 951K2020-07-31: 787K2020-08-14: 1.2M2020-08-31: 2.4M2020-09-15: 3.0M2020-09-30: 3.3M2020-10-15: 3.2M2020-10-30: 3.0M2020-11-13: 2.8M2020-11-30: 2.4M2020-12-15: 2.2M2020-12-31: 4.8M
the 31 Dec 2020 report24 earlier reportsnormal: 869K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Institutional holdings: Many funds opening a new position became public on 16 Feb 2021

Celldex Therapeutics saw 41 13F filers open a new position in the quarter ended 31 Dec 2020, 6.8× the same quarter last year.

This period
41 (the quarter ended 31 Dec 2020)
Normal quarter (median of 8 earlier)
9
Typical spread (median absolute deviation)
3
How far from its usual level
+7.2
Same quarter last year
6
History used
2,649 days
2018-12-31: 92019-03-31: 92019-06-30: 112019-09-30: 42019-12-31: 62020-03-31: 62020-06-30: 362020-09-30: 332020-12-31: 41
the quarter ended 31 Dec 20208 earlier quartersnormal: 9

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

17 Nov 2020confirmed

Confirmed across sources Institutional holdings and Short interest and volume

Celldex Therapeutics (CLDX): saw 33 13F filers open a new position in the quarter ended 30 Sep 2020, 8.2× the same quarter last year, while it had 2.4M shares sold short in the 30 Nov 2020 report, 5.7× the same report last year. Two unrelated kinds of activity within 49 days.

  • Short interest and volume: Short interest spike, became public on 27 Oct 2020
  • Institutional holdings: Many funds opening a new position, became public on 16 Nov 2020
  • Short interest and volume: Short interest spike, became public on 11 Nov 2020
  • Short interest and volume: Short interest spike, became public on 25 Nov 2020
  • Short interest and volume: Short interest spike, became public on 10 Dec 2020
2018-09-30: 62018-12-31: 92019-03-31: 92019-06-30: 112019-09-30: 42019-12-31: 62020-03-31: 62020-06-30: 362020-09-30: 33
The quarter ended 30 Sep 2020 against the 8 quarters before it. this quarterearliernormal: 7.5
See the evidence (5 changes)

Short interest and volume: Short interest spike became public on 27 Oct 2020

Celldex Therapeutics had 3.2M shares sold short in the 15 Oct 2020 report, 6.8× the same report last year.

This period
3.2M (the 15 Oct 2020 report)
Normal report (median of 24 earlier)
398K
Typical spread (median absolute deviation)
123K
How far from its usual level
+15.6
Same report last year
480K
History used
1,021 days
2019-10-15: 480K2019-10-31: 570K2019-11-15: 331K2019-11-29: 431K2019-12-13: 351K2019-12-31: 310K2020-01-15: 284K2020-01-31: 266K2020-02-14: 244K2020-02-28: 381K2020-03-13: 415K2020-03-31: 322K2020-04-15: 315K2020-04-30: 307K2020-05-15: 264K2020-05-29: 301K2020-06-15: 2.3M2020-06-30: 1.5M2020-07-15: 951K2020-07-31: 787K2020-08-14: 1.2M2020-08-31: 2.4M2020-09-15: 3.0M2020-09-30: 3.3M2020-10-15: 3.2M
the 15 Oct 2020 report24 earlier reportsnormal: 398K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Institutional holdings: Many funds opening a new position became public on 16 Nov 2020

Celldex Therapeutics saw 33 13F filers open a new position in the quarter ended 30 Sep 2020, 8.2× the same quarter last year.

This period
33 (the quarter ended 30 Sep 2020)
Normal quarter (median of 8 earlier)
7.5
Typical spread (median absolute deviation)
1.5
How far from its usual level
+8.5
Same quarter last year
4
History used
2,557 days
2018-09-30: 62018-12-31: 92019-03-31: 92019-06-30: 112019-09-30: 42019-12-31: 62020-03-31: 62020-06-30: 362020-09-30: 33
the quarter ended 30 Sep 20208 earlier quartersnormal: 7.5

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Short interest and volume: Short interest spike became public on 11 Nov 2020

Celldex Therapeutics had 3.0M shares sold short in the 30 Oct 2020 report, 5.2× the same report last year.

This period
3.0M (the 30 Oct 2020 report)
Normal report (median of 24 earlier)
398K
Typical spread (median absolute deviation)
133K
How far from its usual level
+13.1
Same report last year
570K
History used
1,036 days
2019-10-31: 570K2019-11-15: 331K2019-11-29: 431K2019-12-13: 351K2019-12-31: 310K2020-01-15: 284K2020-01-31: 266K2020-02-14: 244K2020-02-28: 381K2020-03-13: 415K2020-03-31: 322K2020-04-15: 315K2020-04-30: 307K2020-05-15: 264K2020-05-29: 301K2020-06-15: 2.3M2020-06-30: 1.5M2020-07-15: 951K2020-07-31: 787K2020-08-14: 1.2M2020-08-31: 2.4M2020-09-15: 3.0M2020-09-30: 3.3M2020-10-15: 3.2M2020-10-30: 3.0M
the 30 Oct 2020 report24 earlier reportsnormal: 398K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 25 Nov 2020

Celldex Therapeutics had 2.8M shares sold short in the 13 Nov 2020 report, 8.5× the same report last year.

This period
2.8M (the 13 Nov 2020 report)
Normal report (median of 24 earlier)
398K
Typical spread (median absolute deviation)
133K
How far from its usual level
+12.3
Same report last year
331K
History used
1,050 days
2019-11-15: 331K2019-11-29: 431K2019-12-13: 351K2019-12-31: 310K2020-01-15: 284K2020-01-31: 266K2020-02-14: 244K2020-02-28: 381K2020-03-13: 415K2020-03-31: 322K2020-04-15: 315K2020-04-30: 307K2020-05-15: 264K2020-05-29: 301K2020-06-15: 2.3M2020-06-30: 1.5M2020-07-15: 951K2020-07-31: 787K2020-08-14: 1.2M2020-08-31: 2.4M2020-09-15: 3.0M2020-09-30: 3.3M2020-10-15: 3.2M2020-10-30: 3.0M2020-11-13: 2.8M
the 13 Nov 2020 report24 earlier reportsnormal: 398K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 10 Dec 2020

Celldex Therapeutics had 2.4M shares sold short in the 30 Nov 2020 report, 5.7× the same report last year.

This period
2.4M (the 30 Nov 2020 report)
Normal report (median of 24 earlier)
423K
Typical spread (median absolute deviation)
169K
How far from its usual level
+8.0
Same report last year
431K
History used
1,067 days
2019-11-29: 431K2019-12-13: 351K2019-12-31: 310K2020-01-15: 284K2020-01-31: 266K2020-02-14: 244K2020-02-28: 381K2020-03-13: 415K2020-03-31: 322K2020-04-15: 315K2020-04-30: 307K2020-05-15: 264K2020-05-29: 301K2020-06-15: 2.3M2020-06-30: 1.5M2020-07-15: 951K2020-07-31: 787K2020-08-14: 1.2M2020-08-31: 2.4M2020-09-15: 3.0M2020-09-30: 3.3M2020-10-15: 3.2M2020-10-30: 3.0M2020-11-13: 2.8M2020-11-30: 2.4M
the 30 Nov 2020 report24 earlier reportsnormal: 423K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

30 Jun 2020confirmed

Confirmed across sources Insiders and Short interest and volume

Celldex Therapeutics (CLDX): had 5 insiders buy $119K of its shares on the open market within 30 days (5 filings), while it had 2.3M shares sold short in the 15 Jun 2020 report, 1.9× the same report last year. Two unrelated kinds of activity within 33 days.

  • Insiders: Clustered insider buying, became public on 11 Jun 2020
  • Short interest and volume: Short interest spike, became public on 25 Jun 2020
  • Short interest and volume: Short interest spike, became public on 11 Jul 2020
2019-06-14: 1.2M2019-06-28: 1.2M2019-07-15: 1.0M2019-07-31: 1.2M2019-08-15: 1.2M2019-08-30: 894K2019-09-13: 594K2019-09-30: 520K2019-10-15: 480K2019-10-31: 570K2019-11-15: 331K2019-11-29: 431K2019-12-13: 351K2019-12-31: 310K2020-01-15: 284K2020-01-31: 266K2020-02-14: 244K2020-02-28: 381K2020-03-13: 415K2020-03-31: 322K2020-04-15: 315K2020-04-30: 307K2020-05-15: 264K2020-05-29: 301K2020-06-15: 2.3M
The 15 Jun 2020 report against the 24 reports before it. this reportearliernormal: 398K
See the evidence (3 changes)

Insiders: Clustered insider buying became public on 11 Jun 2020

Celldex Therapeutics had 5 insiders buy $119K of its shares on the open market within 30 days (5 filings).

Independent buyers
5
Purchase filings (Form 4, code P)
5
Total bought
$119K
Window
12 May 2020 to 11 Jun 2020

Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

Short interest and volume: Short interest spike became public on 25 Jun 2020

Celldex Therapeutics had 2.3M shares sold short in the 15 Jun 2020 report, 1.9× the same report last year.

This period
2.3M (the 15 Jun 2020 report)
Normal report (median of 24 earlier)
398K
Typical spread (median absolute deviation)
118K
How far from its usual level
+10.9
Same report last year
1.2M
History used
899 days
2019-06-14: 1.2M2019-06-28: 1.2M2019-07-15: 1.0M2019-07-31: 1.2M2019-08-15: 1.2M2019-08-30: 894K2019-09-13: 594K2019-09-30: 520K2019-10-15: 480K2019-10-31: 570K2019-11-15: 331K2019-11-29: 431K2019-12-13: 351K2019-12-31: 310K2020-01-15: 284K2020-01-31: 266K2020-02-14: 244K2020-02-28: 381K2020-03-13: 415K2020-03-31: 322K2020-04-15: 315K2020-04-30: 307K2020-05-15: 264K2020-05-29: 301K2020-06-15: 2.3M
the 15 Jun 2020 report24 earlier reportsnormal: 398K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Short interest and volume: Short interest spike became public on 11 Jul 2020

Celldex Therapeutics had 1.5M shares sold short in the 30 Jun 2020 report, 1.2× the same report last year.

This period
1.5M (the 30 Jun 2020 report)
Normal report (median of 24 earlier)
398K
Typical spread (median absolute deviation)
118K
How far from its usual level
+6.4
Same report last year
1.2M
History used
914 days
2019-06-28: 1.2M2019-07-15: 1.0M2019-07-31: 1.2M2019-08-15: 1.2M2019-08-30: 894K2019-09-13: 594K2019-09-30: 520K2019-10-15: 480K2019-10-31: 570K2019-11-15: 331K2019-11-29: 431K2019-12-13: 351K2019-12-31: 310K2020-01-15: 284K2020-01-31: 266K2020-02-14: 244K2020-02-28: 381K2020-03-13: 415K2020-03-31: 322K2020-04-15: 315K2020-04-30: 307K2020-05-15: 264K2020-05-29: 301K2020-06-15: 2.3M2020-06-30: 1.5M
the 30 Jun 2020 report24 earlier reportsnormal: 398K

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

Check it at the source: FINRA short interest data.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 15 Jul 2026Filings record

    Director or officer change

  2. 26 Jun 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  3. 26 Jun 2026Filings record

    Director or officer change

  4. 6 Jun 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  5. 6 Jun 2025Filings record

    Director or officer change

  6. 5 Mar 2025Lobbying change

    registered for federal lobbying for the first time in our data (Akin Gump Strauss Hauer & Feld).

    See the evidence (1 source record)
    Source coverage starts
    7 Oct 2008
    Earlier events of other kinds
    0

    "First" means first in our data: it fires only when the source's history began at least 365 days earlier.

  7. 5 Mar 2025Lobbying record

    CELLDEX THERAPEUTICS, INC.: new lobbying registration (AKIN GUMP STRAUSS HAUER & FELD) (dated 19 Feb 2025)

  8. 13 Nov 2024Insiders record

    Marucci Anthony S (PRESIDENT & CEO) bought 11,500 shares of CLDX ($308,430) (dated 12 Nov 2024)

  9. 14 Jun 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  10. 14 Jun 2024Filings record

    Director or officer change

  11. 15 May 2024Institutional holdings change

    saw 40 13F filers open a new position in the quarter ended 31 Mar 2024, 2.0× the same quarter last year.

    Same quarter last year: 20; its normal quarter is 19.

    See the evidence
    This period
    40 (the quarter ended 31 Mar 2024)
    Normal quarter (median of 8 earlier)
    19
    Typical spread (median absolute deviation)
    3.5
    How far from its usual level
    +4.0
    Same quarter last year
    20
    History used
    3,835 days
    2022-03-31: 182022-06-30: 182022-09-30: 242022-12-31: 232023-03-31: 202023-06-30: 162023-09-30: 132023-12-31: 272024-03-31: 40
    the quarter ended 31 Mar 20248 earlier quartersnormal: 19

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  12. 21 Feb 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  13. 21 Feb 2023Filings record

    Director or officer change

  14. 14 Aug 2021Insiders record

    Jimenez Freddy A. (SVP & General Counsel) bought 430 shares of CLDX ($19,900) (dated 13 Aug 2021)

  15. 1 Jul 2021Filings record

    Director or officer change

  16. 17 Jun 2021Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  17. 17 Jun 2021Filings record

    Director or officer change

  18. 16 Feb 2021several at once

    had 4.8M shares sold short in the 31 Dec 2020 report, 16× the same report last year, while it saw 41 13F filers open a new position in the quarter ended 31 Dec 2020, 6.8× the same quarter last year. Two unrelated kinds of activity within 28 days.

    See the evidence (2 changes)

    Short interest and volume: Short interest spike became public on 13 Jan 2021

    Celldex Therapeutics had 4.8M shares sold short in the 31 Dec 2020 report, 16× the same report last year.

    This period
    4.8M (the 31 Dec 2020 report)
    Normal report (median of 24 earlier)
    869K
    Typical spread (median absolute deviation)
    604K
    How far from its usual level
    +4.4
    Same report last year
    310K
    History used
    1,098 days
    2019-12-31: 310K2020-01-15: 284K2020-01-31: 266K2020-02-14: 244K2020-02-28: 381K2020-03-13: 415K2020-03-31: 322K2020-04-15: 315K2020-04-30: 307K2020-05-15: 264K2020-05-29: 301K2020-06-15: 2.3M2020-06-30: 1.5M2020-07-15: 951K2020-07-31: 787K2020-08-14: 1.2M2020-08-31: 2.4M2020-09-15: 3.0M2020-09-30: 3.3M2020-10-15: 3.2M2020-10-30: 3.0M2020-11-13: 2.8M2020-11-30: 2.4M2020-12-15: 2.2M2020-12-31: 4.8M
    the 31 Dec 2020 report24 earlier reportsnormal: 869K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Institutional holdings: Many funds opening a new position became public on 16 Feb 2021

    Celldex Therapeutics saw 41 13F filers open a new position in the quarter ended 31 Dec 2020, 6.8× the same quarter last year.

    This period
    41 (the quarter ended 31 Dec 2020)
    Normal quarter (median of 8 earlier)
    9
    Typical spread (median absolute deviation)
    3
    How far from its usual level
    +7.2
    Same quarter last year
    6
    History used
    2,649 days
    2018-12-31: 92019-03-31: 92019-06-30: 112019-09-30: 42019-12-31: 62020-03-31: 62020-06-30: 362020-09-30: 332020-12-31: 41
    the quarter ended 31 Dec 20208 earlier quartersnormal: 9

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  19. 16 Feb 2021Institutional holdings change

    saw 41 13F filers open a new position in the quarter ended 31 Dec 2020, 6.8× the same quarter last year.

    Same quarter last year: 6; its normal quarter is 9.

    See the evidence
    This period
    41 (the quarter ended 31 Dec 2020)
    Normal quarter (median of 8 earlier)
    9
    Typical spread (median absolute deviation)
    3
    How far from its usual level
    +7.2
    Same quarter last year
    6
    History used
    2,649 days
    2018-12-31: 92019-03-31: 92019-06-30: 112019-09-30: 42019-12-31: 62020-03-31: 62020-06-30: 362020-09-30: 332020-12-31: 41
    the quarter ended 31 Dec 20208 earlier quartersnormal: 9

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  20. 13 Jan 2021Short interest and volume change

    had 4.8M shares sold short in the 31 Dec 2020 report, 16× the same report last year.

    Same report last year: 310K; its normal report is 869K.

    See the evidence
    This period
    4.8M (the 31 Dec 2020 report)
    Normal report (median of 24 earlier)
    869K
    Typical spread (median absolute deviation)
    604K
    How far from its usual level
    +4.4
    Same report last year
    310K
    History used
    1,098 days
    2019-12-31: 310K2020-01-15: 284K2020-01-31: 266K2020-02-14: 244K2020-02-28: 381K2020-03-13: 415K2020-03-31: 322K2020-04-15: 315K2020-04-30: 307K2020-05-15: 264K2020-05-29: 301K2020-06-15: 2.3M2020-06-30: 1.5M2020-07-15: 951K2020-07-31: 787K2020-08-14: 1.2M2020-08-31: 2.4M2020-09-15: 3.0M2020-09-30: 3.3M2020-10-15: 3.2M2020-10-30: 3.0M2020-11-13: 2.8M2020-11-30: 2.4M2020-12-15: 2.2M2020-12-31: 4.8M
    the 31 Dec 2020 report24 earlier reportsnormal: 869K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  21. 4 Jan 2021Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  22. 4 Jan 2021Filings record

    Director or officer change

  23. 10 Dec 2020Short interest and volume change

    had 2.4M shares sold short in the 30 Nov 2020 report, 5.7× the same report last year.

    Same report last year: 431K; its normal report is 423K.

    See the evidence
    This period
    2.4M (the 30 Nov 2020 report)
    Normal report (median of 24 earlier)
    423K
    Typical spread (median absolute deviation)
    169K
    How far from its usual level
    +8.0
    Same report last year
    431K
    History used
    1,067 days
    2019-11-29: 431K2019-12-13: 351K2019-12-31: 310K2020-01-15: 284K2020-01-31: 266K2020-02-14: 244K2020-02-28: 381K2020-03-13: 415K2020-03-31: 322K2020-04-15: 315K2020-04-30: 307K2020-05-15: 264K2020-05-29: 301K2020-06-15: 2.3M2020-06-30: 1.5M2020-07-15: 951K2020-07-31: 787K2020-08-14: 1.2M2020-08-31: 2.4M2020-09-15: 3.0M2020-09-30: 3.3M2020-10-15: 3.2M2020-10-30: 3.0M2020-11-13: 2.8M2020-11-30: 2.4M
    the 30 Nov 2020 report24 earlier reportsnormal: 423K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  24. 25 Nov 2020Short interest and volume change

    had 2.8M shares sold short in the 13 Nov 2020 report, 8.5× the same report last year.

    Same report last year: 331K; its normal report is 398K.

    See the evidence
    This period
    2.8M (the 13 Nov 2020 report)
    Normal report (median of 24 earlier)
    398K
    Typical spread (median absolute deviation)
    133K
    How far from its usual level
    +12.3
    Same report last year
    331K
    History used
    1,050 days
    2019-11-15: 331K2019-11-29: 431K2019-12-13: 351K2019-12-31: 310K2020-01-15: 284K2020-01-31: 266K2020-02-14: 244K2020-02-28: 381K2020-03-13: 415K2020-03-31: 322K2020-04-15: 315K2020-04-30: 307K2020-05-15: 264K2020-05-29: 301K2020-06-15: 2.3M2020-06-30: 1.5M2020-07-15: 951K2020-07-31: 787K2020-08-14: 1.2M2020-08-31: 2.4M2020-09-15: 3.0M2020-09-30: 3.3M2020-10-15: 3.2M2020-10-30: 3.0M2020-11-13: 2.8M
    the 13 Nov 2020 report24 earlier reportsnormal: 398K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  25. 17 Nov 2020several at once

    saw 33 13F filers open a new position in the quarter ended 30 Sep 2020, 8.2× the same quarter last year, while it had 2.4M shares sold short in the 30 Nov 2020 report, 5.7× the same report last year. Two unrelated kinds of activity within 49 days.

    See the evidence (5 changes)

    Short interest and volume: Short interest spike became public on 27 Oct 2020

    Celldex Therapeutics had 3.2M shares sold short in the 15 Oct 2020 report, 6.8× the same report last year.

    This period
    3.2M (the 15 Oct 2020 report)
    Normal report (median of 24 earlier)
    398K
    Typical spread (median absolute deviation)
    123K
    How far from its usual level
    +15.6
    Same report last year
    480K
    History used
    1,021 days
    2019-10-15: 480K2019-10-31: 570K2019-11-15: 331K2019-11-29: 431K2019-12-13: 351K2019-12-31: 310K2020-01-15: 284K2020-01-31: 266K2020-02-14: 244K2020-02-28: 381K2020-03-13: 415K2020-03-31: 322K2020-04-15: 315K2020-04-30: 307K2020-05-15: 264K2020-05-29: 301K2020-06-15: 2.3M2020-06-30: 1.5M2020-07-15: 951K2020-07-31: 787K2020-08-14: 1.2M2020-08-31: 2.4M2020-09-15: 3.0M2020-09-30: 3.3M2020-10-15: 3.2M
    the 15 Oct 2020 report24 earlier reportsnormal: 398K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Institutional holdings: Many funds opening a new position became public on 16 Nov 2020

    Celldex Therapeutics saw 33 13F filers open a new position in the quarter ended 30 Sep 2020, 8.2× the same quarter last year.

    This period
    33 (the quarter ended 30 Sep 2020)
    Normal quarter (median of 8 earlier)
    7.5
    Typical spread (median absolute deviation)
    1.5
    How far from its usual level
    +8.5
    Same quarter last year
    4
    History used
    2,557 days
    2018-09-30: 62018-12-31: 92019-03-31: 92019-06-30: 112019-09-30: 42019-12-31: 62020-03-31: 62020-06-30: 362020-09-30: 33
    the quarter ended 30 Sep 20208 earlier quartersnormal: 7.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Short interest and volume: Short interest spike became public on 11 Nov 2020

    Celldex Therapeutics had 3.0M shares sold short in the 30 Oct 2020 report, 5.2× the same report last year.

    This period
    3.0M (the 30 Oct 2020 report)
    Normal report (median of 24 earlier)
    398K
    Typical spread (median absolute deviation)
    133K
    How far from its usual level
    +13.1
    Same report last year
    570K
    History used
    1,036 days
    2019-10-31: 570K2019-11-15: 331K2019-11-29: 431K2019-12-13: 351K2019-12-31: 310K2020-01-15: 284K2020-01-31: 266K2020-02-14: 244K2020-02-28: 381K2020-03-13: 415K2020-03-31: 322K2020-04-15: 315K2020-04-30: 307K2020-05-15: 264K2020-05-29: 301K2020-06-15: 2.3M2020-06-30: 1.5M2020-07-15: 951K2020-07-31: 787K2020-08-14: 1.2M2020-08-31: 2.4M2020-09-15: 3.0M2020-09-30: 3.3M2020-10-15: 3.2M2020-10-30: 3.0M
    the 30 Oct 2020 report24 earlier reportsnormal: 398K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 25 Nov 2020

    Celldex Therapeutics had 2.8M shares sold short in the 13 Nov 2020 report, 8.5× the same report last year.

    This period
    2.8M (the 13 Nov 2020 report)
    Normal report (median of 24 earlier)
    398K
    Typical spread (median absolute deviation)
    133K
    How far from its usual level
    +12.3
    Same report last year
    331K
    History used
    1,050 days
    2019-11-15: 331K2019-11-29: 431K2019-12-13: 351K2019-12-31: 310K2020-01-15: 284K2020-01-31: 266K2020-02-14: 244K2020-02-28: 381K2020-03-13: 415K2020-03-31: 322K2020-04-15: 315K2020-04-30: 307K2020-05-15: 264K2020-05-29: 301K2020-06-15: 2.3M2020-06-30: 1.5M2020-07-15: 951K2020-07-31: 787K2020-08-14: 1.2M2020-08-31: 2.4M2020-09-15: 3.0M2020-09-30: 3.3M2020-10-15: 3.2M2020-10-30: 3.0M2020-11-13: 2.8M
    the 13 Nov 2020 report24 earlier reportsnormal: 398K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 10 Dec 2020

    Celldex Therapeutics had 2.4M shares sold short in the 30 Nov 2020 report, 5.7× the same report last year.

    This period
    2.4M (the 30 Nov 2020 report)
    Normal report (median of 24 earlier)
    423K
    Typical spread (median absolute deviation)
    169K
    How far from its usual level
    +8.0
    Same report last year
    431K
    History used
    1,067 days
    2019-11-29: 431K2019-12-13: 351K2019-12-31: 310K2020-01-15: 284K2020-01-31: 266K2020-02-14: 244K2020-02-28: 381K2020-03-13: 415K2020-03-31: 322K2020-04-15: 315K2020-04-30: 307K2020-05-15: 264K2020-05-29: 301K2020-06-15: 2.3M2020-06-30: 1.5M2020-07-15: 951K2020-07-31: 787K2020-08-14: 1.2M2020-08-31: 2.4M2020-09-15: 3.0M2020-09-30: 3.3M2020-10-15: 3.2M2020-10-30: 3.0M2020-11-13: 2.8M2020-11-30: 2.4M
    the 30 Nov 2020 report24 earlier reportsnormal: 423K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  26. 16 Nov 2020Institutional holdings change

    saw 33 13F filers open a new position in the quarter ended 30 Sep 2020, 8.2× the same quarter last year.

    Same quarter last year: 4; its normal quarter is 7.5.

    See the evidence
    This period
    33 (the quarter ended 30 Sep 2020)
    Normal quarter (median of 8 earlier)
    7.5
    Typical spread (median absolute deviation)
    1.5
    How far from its usual level
    +8.5
    Same quarter last year
    4
    History used
    2,557 days
    2018-09-30: 62018-12-31: 92019-03-31: 92019-06-30: 112019-09-30: 42019-12-31: 62020-03-31: 62020-06-30: 362020-09-30: 33
    the quarter ended 30 Sep 20208 earlier quartersnormal: 7.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  27. 11 Nov 2020Short interest and volume change

    had 3.0M shares sold short in the 30 Oct 2020 report, 5.2× the same report last year.

    Same report last year: 570K; its normal report is 398K.

    See the evidence
    This period
    3.0M (the 30 Oct 2020 report)
    Normal report (median of 24 earlier)
    398K
    Typical spread (median absolute deviation)
    133K
    How far from its usual level
    +13.1
    Same report last year
    570K
    History used
    1,036 days
    2019-10-31: 570K2019-11-15: 331K2019-11-29: 431K2019-12-13: 351K2019-12-31: 310K2020-01-15: 284K2020-01-31: 266K2020-02-14: 244K2020-02-28: 381K2020-03-13: 415K2020-03-31: 322K2020-04-15: 315K2020-04-30: 307K2020-05-15: 264K2020-05-29: 301K2020-06-15: 2.3M2020-06-30: 1.5M2020-07-15: 951K2020-07-31: 787K2020-08-14: 1.2M2020-08-31: 2.4M2020-09-15: 3.0M2020-09-30: 3.3M2020-10-15: 3.2M2020-10-30: 3.0M
    the 30 Oct 2020 report24 earlier reportsnormal: 398K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  28. 27 Oct 2020Short interest and volume change

    had 3.2M shares sold short in the 15 Oct 2020 report, 6.8× the same report last year.

    Same report last year: 480K; its normal report is 398K.

    See the evidence
    This period
    3.2M (the 15 Oct 2020 report)
    Normal report (median of 24 earlier)
    398K
    Typical spread (median absolute deviation)
    123K
    How far from its usual level
    +15.6
    Same report last year
    480K
    History used
    1,021 days
    2019-10-15: 480K2019-10-31: 570K2019-11-15: 331K2019-11-29: 431K2019-12-13: 351K2019-12-31: 310K2020-01-15: 284K2020-01-31: 266K2020-02-14: 244K2020-02-28: 381K2020-03-13: 415K2020-03-31: 322K2020-04-15: 315K2020-04-30: 307K2020-05-15: 264K2020-05-29: 301K2020-06-15: 2.3M2020-06-30: 1.5M2020-07-15: 951K2020-07-31: 787K2020-08-14: 1.2M2020-08-31: 2.4M2020-09-15: 3.0M2020-09-30: 3.3M2020-10-15: 3.2M
    the 15 Oct 2020 report24 earlier reportsnormal: 398K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  29. 10 Oct 2020Short interest and volume change

    had 3.3M shares sold short in the 30 Sep 2020 report, 6.3× the same report last year.

    Same report last year: 520K; its normal report is 398K.

    See the evidence
    This period
    3.3M (the 30 Sep 2020 report)
    Normal report (median of 24 earlier)
    398K
    Typical spread (median absolute deviation)
    118K
    How far from its usual level
    +16.5
    Same report last year
    520K
    History used
    1,006 days
    2019-09-30: 520K2019-10-15: 480K2019-10-31: 570K2019-11-15: 331K2019-11-29: 431K2019-12-13: 351K2019-12-31: 310K2020-01-15: 284K2020-01-31: 266K2020-02-14: 244K2020-02-28: 381K2020-03-13: 415K2020-03-31: 322K2020-04-15: 315K2020-04-30: 307K2020-05-15: 264K2020-05-29: 301K2020-06-15: 2.3M2020-06-30: 1.5M2020-07-15: 951K2020-07-31: 787K2020-08-14: 1.2M2020-08-31: 2.4M2020-09-15: 3.0M2020-09-30: 3.3M
    the 30 Sep 2020 report24 earlier reportsnormal: 398K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  30. 25 Sep 2020Short interest and volume change

    had 3.0M shares sold short in the 15 Sep 2020 report, 5.0× the same report last year.

    Same report last year: 594K; its normal report is 398K.

    See the evidence
    This period
    3.0M (the 15 Sep 2020 report)
    Normal report (median of 24 earlier)
    398K
    Typical spread (median absolute deviation)
    118K
    How far from its usual level
    +14.8
    Same report last year
    594K
    History used
    991 days
    2019-09-13: 594K2019-09-30: 520K2019-10-15: 480K2019-10-31: 570K2019-11-15: 331K2019-11-29: 431K2019-12-13: 351K2019-12-31: 310K2020-01-15: 284K2020-01-31: 266K2020-02-14: 244K2020-02-28: 381K2020-03-13: 415K2020-03-31: 322K2020-04-15: 315K2020-04-30: 307K2020-05-15: 264K2020-05-29: 301K2020-06-15: 2.3M2020-06-30: 1.5M2020-07-15: 951K2020-07-31: 787K2020-08-14: 1.2M2020-08-31: 2.4M2020-09-15: 3.0M
    the 15 Sep 2020 report24 earlier reportsnormal: 398K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  31. 11 Sep 2020Short interest and volume change

    had 2.4M shares sold short in the 31 Aug 2020 report, 2.7× the same report last year.

    Same report last year: 894K; its normal report is 398K.

    See the evidence
    This period
    2.4M (the 31 Aug 2020 report)
    Normal report (median of 24 earlier)
    398K
    Typical spread (median absolute deviation)
    118K
    How far from its usual level
    +11.6
    Same report last year
    894K
    History used
    976 days
    2019-08-30: 894K2019-09-13: 594K2019-09-30: 520K2019-10-15: 480K2019-10-31: 570K2019-11-15: 331K2019-11-29: 431K2019-12-13: 351K2019-12-31: 310K2020-01-15: 284K2020-01-31: 266K2020-02-14: 244K2020-02-28: 381K2020-03-13: 415K2020-03-31: 322K2020-04-15: 315K2020-04-30: 307K2020-05-15: 264K2020-05-29: 301K2020-06-15: 2.3M2020-06-30: 1.5M2020-07-15: 951K2020-07-31: 787K2020-08-14: 1.2M2020-08-31: 2.4M
    the 31 Aug 2020 report24 earlier reportsnormal: 398K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  32. 26 Aug 2020Short interest and volume change

    had 1.2M shares sold short in the 14 Aug 2020 report, 1.0× the same report last year.

    Same report last year: 1.2M; its normal report is 398K.

    See the evidence
    This period
    1.2M (the 14 Aug 2020 report)
    Normal report (median of 24 earlier)
    398K
    Typical spread (median absolute deviation)
    118K
    How far from its usual level
    +4.6
    Same report last year
    1.2M
    History used
    959 days
    2019-08-15: 1.2M2019-08-30: 894K2019-09-13: 594K2019-09-30: 520K2019-10-15: 480K2019-10-31: 570K2019-11-15: 331K2019-11-29: 431K2019-12-13: 351K2019-12-31: 310K2020-01-15: 284K2020-01-31: 266K2020-02-14: 244K2020-02-28: 381K2020-03-13: 415K2020-03-31: 322K2020-04-15: 315K2020-04-30: 307K2020-05-15: 264K2020-05-29: 301K2020-06-15: 2.3M2020-06-30: 1.5M2020-07-15: 951K2020-07-31: 787K2020-08-14: 1.2M
    the 14 Aug 2020 report24 earlier reportsnormal: 398K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  33. 11 Jul 2020Short interest and volume change

    had 1.5M shares sold short in the 30 Jun 2020 report, 1.2× the same report last year.

    Same report last year: 1.2M; its normal report is 398K.

    See the evidence
    This period
    1.5M (the 30 Jun 2020 report)
    Normal report (median of 24 earlier)
    398K
    Typical spread (median absolute deviation)
    118K
    How far from its usual level
    +6.4
    Same report last year
    1.2M
    History used
    914 days
    2019-06-28: 1.2M2019-07-15: 1.0M2019-07-31: 1.2M2019-08-15: 1.2M2019-08-30: 894K2019-09-13: 594K2019-09-30: 520K2019-10-15: 480K2019-10-31: 570K2019-11-15: 331K2019-11-29: 431K2019-12-13: 351K2019-12-31: 310K2020-01-15: 284K2020-01-31: 266K2020-02-14: 244K2020-02-28: 381K2020-03-13: 415K2020-03-31: 322K2020-04-15: 315K2020-04-30: 307K2020-05-15: 264K2020-05-29: 301K2020-06-15: 2.3M2020-06-30: 1.5M
    the 30 Jun 2020 report24 earlier reportsnormal: 398K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  34. 30 Jun 2020several at once

    had 5 insiders buy $119K of its shares on the open market within 30 days (5 filings), while it had 2.3M shares sold short in the 15 Jun 2020 report, 1.9× the same report last year. Two unrelated kinds of activity within 33 days.

    See the evidence (3 changes)

    Insiders: Clustered insider buying became public on 11 Jun 2020

    Celldex Therapeutics had 5 insiders buy $119K of its shares on the open market within 30 days (5 filings).

    Independent buyers
    5
    Purchase filings (Form 4, code P)
    5
    Total bought
    $119K
    Window
    12 May 2020 to 11 Jun 2020

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

    Short interest and volume: Short interest spike became public on 25 Jun 2020

    Celldex Therapeutics had 2.3M shares sold short in the 15 Jun 2020 report, 1.9× the same report last year.

    This period
    2.3M (the 15 Jun 2020 report)
    Normal report (median of 24 earlier)
    398K
    Typical spread (median absolute deviation)
    118K
    How far from its usual level
    +10.9
    Same report last year
    1.2M
    History used
    899 days
    2019-06-14: 1.2M2019-06-28: 1.2M2019-07-15: 1.0M2019-07-31: 1.2M2019-08-15: 1.2M2019-08-30: 894K2019-09-13: 594K2019-09-30: 520K2019-10-15: 480K2019-10-31: 570K2019-11-15: 331K2019-11-29: 431K2019-12-13: 351K2019-12-31: 310K2020-01-15: 284K2020-01-31: 266K2020-02-14: 244K2020-02-28: 381K2020-03-13: 415K2020-03-31: 322K2020-04-15: 315K2020-04-30: 307K2020-05-15: 264K2020-05-29: 301K2020-06-15: 2.3M
    the 15 Jun 2020 report24 earlier reportsnormal: 398K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Short interest and volume: Short interest spike became public on 11 Jul 2020

    Celldex Therapeutics had 1.5M shares sold short in the 30 Jun 2020 report, 1.2× the same report last year.

    This period
    1.5M (the 30 Jun 2020 report)
    Normal report (median of 24 earlier)
    398K
    Typical spread (median absolute deviation)
    118K
    How far from its usual level
    +6.4
    Same report last year
    1.2M
    History used
    914 days
    2019-06-28: 1.2M2019-07-15: 1.0M2019-07-31: 1.2M2019-08-15: 1.2M2019-08-30: 894K2019-09-13: 594K2019-09-30: 520K2019-10-15: 480K2019-10-31: 570K2019-11-15: 331K2019-11-29: 431K2019-12-13: 351K2019-12-31: 310K2020-01-15: 284K2020-01-31: 266K2020-02-14: 244K2020-02-28: 381K2020-03-13: 415K2020-03-31: 322K2020-04-15: 315K2020-04-30: 307K2020-05-15: 264K2020-05-29: 301K2020-06-15: 2.3M2020-06-30: 1.5M
    the 30 Jun 2020 report24 earlier reportsnormal: 398K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  35. 25 Jun 2020Short interest and volume change

    had 2.3M shares sold short in the 15 Jun 2020 report, 1.9× the same report last year.

    Same report last year: 1.2M; its normal report is 398K.

    See the evidence
    This period
    2.3M (the 15 Jun 2020 report)
    Normal report (median of 24 earlier)
    398K
    Typical spread (median absolute deviation)
    118K
    How far from its usual level
    +10.9
    Same report last year
    1.2M
    History used
    899 days
    2019-06-14: 1.2M2019-06-28: 1.2M2019-07-15: 1.0M2019-07-31: 1.2M2019-08-15: 1.2M2019-08-30: 894K2019-09-13: 594K2019-09-30: 520K2019-10-15: 480K2019-10-31: 570K2019-11-15: 331K2019-11-29: 431K2019-12-13: 351K2019-12-31: 310K2020-01-15: 284K2020-01-31: 266K2020-02-14: 244K2020-02-28: 381K2020-03-13: 415K2020-03-31: 322K2020-04-15: 315K2020-04-30: 307K2020-05-15: 264K2020-05-29: 301K2020-06-15: 2.3M
    the 15 Jun 2020 report24 earlier reportsnormal: 398K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  36. 18 Jun 2020Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  37. 18 Jun 2020Filings record

    Director or officer change

  38. 13 Jun 2020Insiders record

    Young Diane C. (SVP, Chief Medical Officer) bought 2,115 shares of CLDX ($10,004) (dated 12 Jun 2020)

  39. 12 Jun 2020Insiders record

    Cavanaugh Sarah (SVP of Corp Affairs & Admin.) bought 1,050 shares of CLDX ($5,072) (dated 11 Jun 2020)

  40. 11 Jun 2020Insiders change

    had 5 insiders buy $119K of its shares on the open market within 30 days (5 filings).

    Who bought: Heath-Chiozzi Margo, Marino James J, Martin Samuel Bates, Marucci Anthony S and 1 more.

    See the evidence (5 source records)
    Independent buyers
    5
    Purchase filings (Form 4, code P)
    5
    Total bought
    $119K
    Window
    12 May 2020 to 11 Jun 2020

    Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.

Showing the newest 40 of 66 entries; narrow the window or the kind of data to see older ones.

Not listed: 149 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0000744218
Ticker
CLDX
Domain
celldex.com
Employer name
Celldex Therapeutics, Inc. (1 unverified)
Hq location
NJ|HAMPTON|08827 (1 unverified)
Lobbying client
celldex therapeutics
Name
AVANT IMMUNOTHERAPEUTICS INC, Celldex Therapeutics, Inc, Celldex Therapeutics Switzerland GmbH, T CELL SCIENCES INC
Uei
EGSNNDJBMAG5
Wikidata
Q30281437
  • DOL H-1B labor condition applications and PERM certifications40 data points8 Nov 2021 to 5 Jan 2026
  • Federal lobbying disclosures (LDA)1 record, 21 data points19 Feb 2025 to 30 Sep 2026
  • SEC Form 13F institutional holdings481 data points30 Jun 2013 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)144 records23 Feb 2016 to 5 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)1049 data points31 Dec 2008 to 28 Oct 2026
  • SEC Form 4 insider transactions43 records, 104 data points6 Sep 2016 to 8 Dec 2025
  • FINRA short interest (twice monthly)636 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
  • USASpending.gov federal awards51 data points6 Sep 2011 to 28 Apr 2023